Clinical trials: Dose Administration Aids
HIV Infections
Dose Reduction of Lopinavir in Children
To study the pharmacokinetics of low-dose and standard dose, lopinavir/ritonavir in ARV PI naive HIV-1 infected Thai children. To study clinical and immunological efficacy after 48 weeks of lopinavir/ritonavir in PI naïve HIV-1…
- Trial name
- NCT00887120
- Testing
- Lopinavir/ritonavir standard dose According to WHO simplified dosing table, Lopinavir/ritonavir low dose ( 70% of WHO recommended dosing table)
- Where
- Thailand
- Volunteers
- 24 people
- Sponsor
- The HIV Netherlands Australia Thailand Research Collaboration
HIV Infections
HIV Treatment Adherence Dose Determination Trial
The proposed research will conduct the first dose-determination trial to find the optimal number of behavioral counseling sessions (dose) needed to achieve and sustain optimal HIV treatment adherence.
- Trial name
- NCT04577313
- Testing
- Behavioral Self-Regulation Adherence Counseling
- Where
- 2 sites in United States
- Volunteers
- 400 people
- Sponsor
- University of Connecticut
HIV (Human Immunodeficiency Virus)
Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of LP-98 Injection in Healthy Subjects
A randomized, placebo-controlled, single-administration, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of LP-98 injection in healthy subjects in a first-in-human clinical study
- Trial name
- NCT05933824
- Testing
- LP-98 injection
- Where
- China
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Shanxi Kangbao Biological Product Co., Ltd.
HIV-1-infection
Efficacy, Safety and Optimal Dose of VM-1500 in Comparison to Efavirenz Added to Standard-of-care Antiretroviral Therapy
The study is conducted in two stages and open-label stage of the study. At the first stage of the study, the main purpose was to choose the optimal dose of VM-1500 (20 mg or 40 mg per day) in addition to standard-of-care basic…
- Trial name
- NCT02489461
- Testing
- VM-1500, Efavirenz, Antiretroviral therapy (ART)
- Where
- 13 sites in Russia
- Volunteers
- 150 people
- Sponsor
- Viriom
Medication Adherence, HIV Prevention
Single Dose Truvada Study
This study examines tenofovir (TFV) drug concentrations in adults one day after taking a single dose of Truvada® - a pill used to prevent and treat HIV infection.
- Trial name
- NCT03719053
- Testing
- Tenofovir
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
HIV Infection
Bryostatin-1 Effect on HIV-1 Latency and Reservoir in HIV-1 Infected Patients Receiving Antiretroviral Treatment
Phase I, randomized, double blind, placebo-controlled, dose-finding trial. The trial´s goal is to evaluate two different doses of Bryostatin on HIV-1 latency and reservoir in HIV-1 infected patients receiving antiretroviral…
- Trial name
- BRYOLAT (NCT02269605)
- Testing
- Bryostatin 1 (10ug/m2), Bryostatin 1 (20ug/m2)
- Where
- Spain
- Volunteers
- 12 people
- Sponsor
- Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
HIV Infections
Atazanavir Used in Combination With Other Anti-HIV Drugs in HIV-Infected Infants, Children, and Adolescents
The purpose of this study was to find a safe and tolerable dose of the protease inhibitor (PI) atazanavir (ATV), with or without a low-dose boost of the PI ritonavir (RTV), when taken with other anti-HIV drugs in HIV infected…
- Trial name
- NCT00006604
- Testing
- ATV, Ritonavir
- Where
- 36 sites in United States, Puerto Rico and 1 more
- Volunteers
- 195 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Infection, Human Immunodeficiency Virus, HIV Infections
Study to Evaluate a HIV Drug for the Treatment of HIV Infection
The primary purpose of this study is to study the safety and tolerability of a HIV drug and to evaluate a decrease of HIV-1 virus level in blood after treatments in HIV-1 infected patients
- Trial name
- NCT01803074
- Testing
- BMS-955176, Atazanavir, Ritonavir
- Where
- Germany
- Volunteers
- 107 people
- Sponsor
- ViiV Healthcare
HIV
Evaluation of Viral Efficacy and Safety of a Reduced Dose of Stavudine (d4T): THE PHOENIX STUDY
Lipodystrophie, peripheral neuropathy and mitochondrial toxicity has been associated to stavudine at standard doses The aim of this study is to evaluate the efficacy of reduced doses of stavudine (30 mg b.i.d.) in HIV patients…
- Trial name
- NCT00235222
- Testing
- stavudine
- Where
- France
- Volunteers
- 57 people
- Sponsor
- Groupe Hospitalier Pitie-Salpetriere
HIV Infections
Tipranavir/Ritonavir Low Dose Pharmacokinetics in Treatment Naive Patients
The purpose of this study is to identify an optimal dose combination(s) of tipranavir (TPV) and ritonavir (RTV) for antiretroviral treatment naïve HIV-1 infected patients that can be used in pivotal trial by assessing the…
- Trial name
- NCT00530920
- Testing
- tipranavir, ritonavir
- Where
- 12 sites in Germany, Italy and 1 more
- Volunteers
- 85 people
- Sponsor
- Boehringer Ingelheim
HIV Infections, Tuberculosis
Efficacy and Safety of 2 Raltegravir Doses in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis
Raltegravir is a potent antiretroviral agent that could be used as an alternative to efavirenz in HIV-1 infected patients with tuberculosis.
- Trial name
- NCT00822315
- Testing
- efavirenz, raltegravir
- Where
- 9 sites in Brazil, France
- Volunteers
- 155 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Lung Cancer
Radical Lung Radiotherapy Plus Nelfinavir
The aim of this clinical trial is to test whether the drug nelfinavir, which can increase the effectiveness of radiotherapy, can be given safely at the same time as a full dose of radiotherapy for lung cancer.
- Trial name
- NelfLung (NCT01447589)
- Testing
- nelfinavir, Radical Radiotherapy
- Where
- United Kingdom
- Sponsor
- Oxford University Hospitals NHS Trust
HIV Infections, HCV
An Open Label Non-Randomized Dose Escalating Trial to Assess Safety and Tolerability of Alb-Interferon Alfa 2b Every Two Weeks With Ribavirin Among HIV/HCV Coinfected Individuals
This study will determine if Albumin-linked interferon (Albinterferon alfa-2b) every 2 weeks is safe and tolerated by patients infected by both hepatitis C virus (HCV) and human immunodeficiency virus (HIV).
- Trial name
- NCT00489385
- Testing
- Albinterferon, Ribavirin, Albuferon
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
A Dose Escalation Study of Tenofovir Alafenamide in Treatment-Naive Patients
This study evaluated two doses of tenofovir alafenamide versus tenofovir disoproxil fumarate (tenofovir DF).
- Trial name
- NCT00036634
- Testing
- Tenofovir DF, Tenofovir alafenamide
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Gilead Sciences
Anemia, Neutropenia
Treatment of Anemia and Neutropenia in HIV/HCV Coinfected Patients Treated With Pegylated Interferon and Ribavirin
This study is designed to test two separate strategies for treatment of anemia (low hemoglobin) and neutropenia (low white blood cells) in HIV/HCV coinfected patients who are being treated with pegylated interferon and ribavirin.
- Conditions
- Anemia, Neutropenia, Hepatitis C Virus, HIV Infections
- Trial name
- NCT00194857
- Testing
- erythropoietin, GCSF
- Where
- United States
- Sponsor
- Weill Medical College of Cornell University
HIV Infections
Evaluation of Low-dose Darunavir in a Switch Study
This is a switch study to assess the non-inferiority (in terms of efficacy and safety) of darunavir (boosted with ritonavir, DRV/r 400mg/100mg daily) when compared with lopinavir (boosted with ritonavir, LPV/r total dose…
- Trial name
- DRV (NCT02671383)
- Testing
- Darunavir, Lopinavir
- Where
- South Africa
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Willem Daniel Francois Venter
HIV, Hepatitis C
A Methadone Maintenance Treatment Outcome Study in Three Provinces in China
The primary goal of this PHE is to determine the effectiveness of a tailored education program for MMT service providers. It was to be evaluated through methadone dose levels prescribed to new patients after training completion.
- Conditions
- HIV, Hepatitis C, Syphilis, Herpes Simplex Type II
- Trial name
- NCT01315054
- Testing
- MMT provider dosage training, targeted counseling, national guidelines
- Where
- China
- Volunteers
- 4,258 people
- Sponsor
- Centers for Disease Control and Prevention
Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS), Human Immunodeficiency Virus Infections
An Efficacy and Safety Trial of Serostim® in the Maintenance of the Treatment Effect Obtained During the Study of Serostim® in Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome
This is an open-label, multi-center, randomized, parallel-group, maintenance trial of Serostim® in subjects who have completed a prior Serostim® Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS) trial…
- Trial name
- NCT00294918
- Testing
- Serostim®
- Volunteers
- 142 people
- Sponsor
- EMD Serono
Candidiasis, Oral, HIV Infections
Safety and Effectiveness of Giving Lamisil to HIV-Positive Subjects With Thrush Who Have Not Responded to Fluconazole Treatment
The purpose of this study is to see if it is safe and effective to give Lamisil to HIV-positive patients with thrush (a fungal infection) that has not responded to fluconazole.
- Trial name
- NCT00002394
- Testing
- Terbinafine hydrochloride
- Where
- 9 sites in United States
- Volunteers
- 30 people
- Sponsor
- Novartis
HIV Infection
Safety, Tolerability and Immunogenicity Induced by the THV01 Treatment in Patients Infected With HIV-1 Clade B and Treated With Highly Active Antiretroviral Therapy (HAART).
The objectives of this Phase I/II trial is to evaluate the safety, tolerability and immunogenicity of THV01 compared to placebo in HIV-1 infected patients on HAART (highly active antiretroviral therapies).
- Trial name
- NCT02054286
- Testing
- THV01-1, THV01-2
- Where
- 11 sites in Belgium, France
- Volunteers
- 38 people
- Sponsor
- Theravectys S.A.